Table 2.

APSN and APS-related extrarenal manifestationsa

Groupn (%)Exclusionn (%)OR (95% CI)P
a AT, arterial thrombosis; VT, history of large vein thrombosis; Obst, at least 3 spontaneous abortions or one fetal death after 12 wk.
APSN
 APS + AT6 of 8 (75%)non-(APS + AT)27 of 99 (27%)8 (1.9 to 34.3)0.01
 APS + VT5 of 10 (50%)non-(APS + VT)28 of 97 (29%)NS0.28
 APS + Obst9 of 13 (69%)non-(APS + Obst)21 of 80 (26%)6.3 (1.9 to 20.6)0.004
Chronic APSN
 APS + AT5 of 7 (71%)non-(APS + AT)21 of 93 (23%)8.6 (1.9 to 38)0.012
 APS + VT4 of 9 (44%)non-(APS + VT)22 of 91 (24%)NS0.23
 APS + Obst5 of 9 (56%)non-(APS + Obst)18 of 77 (23%)4.1 (1.1 to 15.8)0.053
Acute APSN
 APS + AT3 of 5 (60%)non-(APS + AT)15 of 87 (17%)7.2 (1.4 to 37.9)0.0496
 APS + VT3 of 8 (38%)non-(APS + VT)15 of 84 (18%)NS0.19
 APS + Obst5 of 9 (56%)non-(APS + Obst)12 of 71 (17%)6.1 (1.6 to 23.5)0.018
FCA
 APS + AT4 of 6 (67%)non-(APS + AT)12 of 84 (14%)12 (2.6 to 54.4)0.0084
 APS + VT3 of 8 (38%)non-(APS + VT)13 of 82 (16%)NS0.15
 APS + Obst5 of 9 (56%)non-(APS + Obst)8 of 67 (12%)9.2 (2.4 to 35.3)0.0059